ME
MED
—
NYSE
Diversified Food Producers
Medifast Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
124,0M USD
P/E
—
EV / Rev
-0,1x
Div yield
0,00 %
Op margin
-4,3 %
ROE
-1,1 %
Net margin
-2,8 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$11,03
Open
$10,67
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Medifast Inc provides structured weight loss and metabolic health solutions through its meal replacement products and coaching services.
Business. Medifast Inc. (NYSE: MED) is a food and beverage producer that operates within the Non-Cyclical Consumer Goods & Services sector. The company generates revenue through the sale of products. Specific details regarding its operating segments and geographic mix are not available.
Classification99 %
SectorConsumer Staples
Industry groupDiversified Food Producers
Generated · model-assisted
Sell-side consensus
HOLD2 analysts
0 buy2 hold0 sell
Avg 12m price target12,00
Analyst recommendations
2 analysts · consensus HoldBuy0
Hold2
Sell0
12-month price target
12,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Hold
2 analysts · indicative
Ownership→
American Century Investment Management, Inc.
largest disclosed fund holder
Profitability→
-1,1 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,7 %
Energy+0,6 %+3,3 %+0,0 %
Health Care+0,6 %−0,8 %+0,0 %
Consumer Discretionary+0,4 %+7,7 %−0,2 %
Information Technology+0,3 %+7,8 %−0,3 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to MED. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Medifast Inc. (NYSE: MED) is a food and beverage producer that operates within the Non-Cyclical Consumer Goods & Services sector. The company generates revenue through the sale of products. Specific details regarding its operating segments and geographic mix are not available.
Classification99 %
SectorConsumer Staples
Industry groupDiversified Food Producers
AI synthesis
GENERATEDMedifast operates with a price-to-book ratio of 0.74 and a price-to-tangible-book ratio of 0.74, indicating a discount to its book value. The company's liquidity position is strong, with a current ratio of 4.8 and $71.5 million in cash and equivalents. However, its operating cash flow of $260,000 and negative free cash flow of -$836,000 suggest limited cash generation capacity.
Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of $2.1 million and an operating loss of $3.3 million in Q1 2026. Return on equity and return on assets were -1.07% and -0.84%, respectively, indicating poor capital efficiency. These results contrast sharply with the industry's typical focus on stable margins and brand-driven pricing power.
The company's revenue is concentrated in its direct-to-consumer business model, which accounts for the majority of its operations. This model exposes Medifast to risks related to customer acquisition costs, coach network performance, and digital marketing effectiveness. The company's supply chain optimization initiative in 2024 aimed to align distribution with demand, but the recent inventory levels show only modest changes, with raw materials increasing from $4.9 million to $6.5 million.
Looking ahead, the company expects to shift from transformation to execution in 2026, leveraging its structured weight loss expertise and new metabolic health offerings. However, the Q1 2026 results show a revenue of $76.0 million, and the outlook for FY 2026 remains uncertain given the competitive pressures from new weight loss medications and AI-driven competitors.
The risk assessment highlights medium dilution potential, with the company having mentioned dilution or offering risks in its filings. The valuation adjustments in custom_valuations reflect a cautious view of the company's capital structure and earnings potential. The company's debt-to-equity ratio is 0.0, indicating no leverage, but this also suggests limited financial flexibility.
Recent events include the FASB's ASU 2025-06 on internal-use software accounting, which may impact the company's financial reporting. The company also completed a supply chain optimization initiative in 2024, but the impact on operational efficiency remains to be seen. The company's strategic shift toward metabolic health is a key focus for long-term growth, but execution risks remain high.
Key takeaways
- Medifast trades at a significant discount to book value, with a price-to-book ratio of 0.74.
- The company is unprofitable, with a net loss of $2.1 million and an operating loss of $3.3 million in Q1 2026.
- Revenue is concentrated in a direct-to-consumer model, which exposes the company to customer acquisition and marketing risks.
- The company is transitioning to a metabolic health strategy, but execution risks and competitive pressures remain high.
- The risk assessment indicates medium dilution potential, with the company having mentioned dilution or offering risks in its filings.
Bull / Bear case
Generated · model-assistedBULL CASE · 5
Analysts project 14.1% upside to a consensus price target of $12.00, suggesting undervaluation relative to current market price.
The company maintains a low leverage band with a debt-to-equity ratio of 0.25, indicating a conservative capital structure.
A strong current ratio of 4.69 suggests robust short-term liquidity and ability to meet immediate financial obligations.
Year-over-year free cash flow surged 1,262.9% in the latest period, demonstrating significant improvement in cash generation.
Operating income increased 120.2% year-over-year, indicating a potential turnaround in core operational profitability metrics.
BEAR CASE · 2
Return on equity of -1.07% places the company in the bottom quartile of its Food & Beverages cohort.
The company faces medium dilution risk, which could negatively impact existing shareholder value and earnings per share.
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Revenue $76.0M; Operating income -$3.3M.
Revenue$76.0M
Operating income-$3.3M
Net income-$2.1M
Free cash flow-$836.0k
EPS—
Operating cash flow$260.0k
Financials
Income statement
Revenue$76.0M
Gross profit$51.8M
Operating income-$3.3M
Net income-$2.1M
Margins
Gross margin68.1%
Operating margin-4.3%
Net margin-2.8%
FCF margin-1.1%
Balance sheet
Total assets$252.0M
Total liabilities$54.4M
Total equity$197.7M
Cash & equivalents$71.5M
Long-term debt—
Cash flow
Operating cash flow$260.0k
CapEx$1.1M
Free cash flow-$836.0k
SBC$1.9M
P&L flow · revenue → net income
Highlights
- ▍Revenue $76.0M
- ▍Operating income -$3.3M
- ▍Net margin -2.8%
QUARTERLYFiled 2025-09-30
Q2 2025 · Quarter highlights
Revenue $310.7M; Operating income -$6.4M.
Revenue$310.7M
Operating income-$6.4M
Net income-$553.0k
Free cash flow$7.9M
EPS—
Operating cash flow$12.1M
Financials
Income statement
Revenue$310.7M
Gross profit$223.0M
Operating income-$6.4M
Net income-$553.0k
Margins
Gross margin71.8%
Operating margin-2.1%
Net margin-0.2%
FCF margin2.5%
Balance sheet
Total assets$268.2M
Total liabilities$53.5M
Total equity$214.7M
Cash & equivalents$99.5M
Long-term debt—
Cash flow
Operating cash flow$12.1M
CapEx$4.3M
Free cash flow$7.9M
SBC$5.5M
P&L flow · revenue → net income
Highlights
- ▍Revenue $310.7M
- ▍Operating income -$6.4M
- ▍Net margin -0.2%
QUARTERLYFiled 2025-06-30
Q1 2025 · Quarter highlights
Revenue $221.3M; Operating income -$2.3M.
Revenue$221.3M
Operating income-$2.3M
Net income$1.7M
Free cash flow-$2.9M
EPS—
Operating cash flow$28.0k
Financials
Income statement
Revenue$221.3M
Gross profit$160.9M
Operating income-$2.3M
Net income$1.7M
Margins
Gross margin72.7%
Operating margin-1.1%
Net margin0.8%
FCF margin-1.3%
Balance sheet
Total assets$269.3M
Total liabilities$53.3M
Total equity$216.0M
Cash & equivalents$101.7M
Long-term debt—
Cash flow
Operating cash flow$28.0k
CapEx$2.9M
Free cash flow-$2.9M
SBC$4.6M
P&L flow · revenue → net income
Highlights
- ▍Revenue $221.3M
- ▍Operating income -$2.3M
- ▍Net margin 0.8%
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Revenue $385.8M; Operating income -$14.2M.
Revenue$385.8M
Operating income-$14.2M
Net income-$18.7M
Free cash flow$1.2M
EPS—
Operating cash flow$6.9M
Financials
Income statement
Revenue$385.8M
Gross profit$275.2M
Operating income-$14.2M
Net income-$18.7M
Margins
Gross margin71.3%
Operating margin-3.7%
Net margin-4.8%
FCF margin0.3%
Balance sheet
Total assets$248.0M
Total liabilities$49.1M
Total equity$198.9M
Cash & equivalents$89.3M
Long-term debt—
Cash flow
Operating cash flow$6.9M
CapEx$5.6M
Free cash flow$1.2M
SBC$7.6M
P&L flow · revenue → net income
Highlights
- ▍Revenue $385.8M
- ▍Operating income -$14.2M
- ▍Net margin -4.8%
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Revenue $602.5M; Operating income $2.9M.
Revenue$602.5M
Operating income$2.9M
Net income$2.1M
Free cash flow$17.0M
EPS—
Operating cash flow$24.5M
Financials
Income statement
Revenue$602.5M
Gross profit$444.6M
Operating income$2.9M
Net income$2.1M
Margins
Gross margin73.8%
Operating margin0.5%
Net margin0.3%
FCF margin2.8%
Balance sheet
Total assets$284.2M
Total liabilities$74.1M
Total equity$210.1M
Cash & equivalents$90.9M
Long-term debt—
Cash flow
Operating cash flow$24.5M
CapEx$7.5M
Free cash flow$17.0M
SBC$7.4M
P&L flow · revenue → net income
Highlights
- ▍Revenue $602.5M
- ▍Operating income $2.9M
- ▍Net margin 0.3%
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Revenue $602.5M; Operating income $2.9M.
Revenue$602.5M
Operating income$2.9M
Net income$2.1M
Free cash flow$17.0M
EPS—
Operating cash flow$24.5M
Financials
Income statement
Revenue$602.5M
Gross profit$444.6M
Operating income$2.9M
Net income$2.1M
Margins
Gross margin73.8%
Operating margin0.5%
Net margin0.3%
FCF margin2.8%
Balance sheet
Total assets$284.2M
Total liabilities$74.1M
Total equity$210.1M
Cash & equivalents$90.9M
Long-term debt—
Cash flow
Operating cash flow$24.5M
CapEx$7.5M
Free cash flow$17.0M
SBC$7.4M
P&L flow · revenue → net income
Highlights
- ▍Revenue $602.5M
- ▍Operating income $2.9M
- ▍Net margin 0.3%
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Revenue $1.07B; Operating income $126.4M.
Revenue$1.07B
Operating income$126.4M
Net income$99.4M
Free cash flow$141.2M
EPS—
Operating cash flow$147.7M
Financials
Income statement
Revenue$1.07B
Gross profit$775.9M
Operating income$126.4M
Net income$99.4M
Margins
Gross margin72.4%
Operating margin11.8%
Net margin9.3%
FCF margin13.2%
Balance sheet
Total assets$309.9M
Total liabilities$108.4M
Total equity$201.5M
Cash & equivalents$94.4M
Long-term debt—
Cash flow
Operating cash flow$147.7M
CapEx$6.5M
Free cash flow$141.2M
SBC$8.2M
P&L flow · revenue → net income
Highlights
- ▍Revenue $1.07B
- ▍Operating income $126.4M
- ▍Net margin 9.3%
ANNUALFiled 2023-12-31
FY 2024 · Full-year highlights
Revenue $1.07B; Operating income $126.4M.
Revenue$1.07B
Operating income$126.4M
Net income$99.4M
Free cash flow$141.2M
EPS—
Operating cash flow$147.7M
Financials
Income statement
Revenue$1.07B
Gross profit$775.9M
Operating income$126.4M
Net income$99.4M
Margins
Gross margin72.4%
Operating margin11.8%
Net margin9.3%
FCF margin13.2%
Balance sheet
Total assets$309.9M
Total liabilities$108.4M
Total equity$201.5M
Cash & equivalents$94.4M
Long-term debt—
Cash flow
Operating cash flow$147.7M
CapEx$6.5M
Free cash flow$141.2M
SBC$8.2M
P&L flow · revenue → net income
Highlights
- ▍Revenue $1.07B
- ▍Operating income $126.4M
- ▍Net margin 9.3%
Valuation FY
Market price
$11,27
Market cap
$146.4M
Enterprise valueⓘ
-$22.6M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
-0.1x
EV / Op incomeⓘ
—
EV / OCFⓘ
-86.8x
P / Bⓘ
0.7x
P / Tangible bookⓘ
0.7x
Tangible book
$197.7M
Net cashⓘ
$168.9M
Current ratioⓘ
4.8
Debt / equityⓘ
—
ROAⓘ
-0.8%
ROEⓘ
-1.1%
Cash conversionⓘ
-12.0%
CapEx / revenueⓘ
1.4%
SBC / revenueⓘ
2.5%
Dilution ratioⓘ
-1.0%
Revenue by segment
Business relationships
Business relationships10 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries10
EX21:02ed8d220202EX21:02ed8d220202Subsidiarie97%
EX21:06b9a6eacd7aEX21:06b9a6eacd7aSubsidiarie97%
EX21:5e7cce562940EX21:5e7cce562940Subsidiarie97%Source ↗
EX21:653ae3e38799EX21:653ae3e38799Subsidiarie97%Source ↗
EX21:67d45732a077EX21:67d45732a077Subsidiarie97%Source ↗
EX21:79aeb20fef3bEX21:79aeb20fef3bSubsidiarie97%
EX21:ae5972edb31dEX21:ae5972edb31dSubsidiarie97%
EX21:c0ae1e697b34EX21:c0ae1e697b34Subsidiarie97%
EX21:df5ad664a2e4EX21:df5ad664a2e4Subsidiarie97%
EX21:f3cd805b3f93EX21:f3cd805b3f93Subsidiarie97%
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs MED · multiples and returns
JB
JBS—
JBS
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
TS
TSN—
Tyson Foods Inc
$59,29
21,0B USDP/E
48,3x
— vs self
Div yield
—
— vs self
ROE
2,6 %
+3,7 vs self
MD
MDLZ—
MONDELEZ INTERNATIONAL, INC.
$61,73
80,1B USDP/E
28,9x
— vs self
Div yield
3,3 %
+3,3 vs self
ROE
10,1 %
+11,2 vs self
AD
ADM—
Archer-daniels-midland Co
$78,06
37,8B USDP/E
36,8x
— vs self
Div yield
2,5 %
+2,5 vs self
ROE
4,7 %
+5,8 vs self
KH
KHC—
THE KRAFT HEINZ COMPANY
$26,40
31,3B USDP/E
—
— vs self
Div yield
6,5 %
+6,5 vs self
ROE
-13,8 %
-12,8 vs self
BI
BIP—
BIP.WA
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
GI
GIS—
General Mills Inc
$35,92
19,3B USDP/E
—
— vs self
Div yield
6,6 %
+6,6 vs self
ROE
-1,2 %
-0,1 vs self
PP
PPC—
PILGRIM'S PRIDE LTD.
$27,92
6,6B USDP/E
6,4x
— vs self
Div yield
—
— vs self
ROE
29,4 %
+30,5 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-1,64
Predicted surprise
-0,02
Beat probability
45 %
Analysts
2
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-07-14 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,64 |
| Revenue | —no estimate | —no estimate | 279,7M USD |
| Operating income | —no estimate | —no estimate | -22,9M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution2 analysts
Strong buy0
Buy0
Hold2
Sell0
Strong sell0
12-month price target$12,00 · Median $12,00
Low $12,00High $12,00
Operating income · consensus-22,9M USD
EPS surprise
−3,7 %
reported vs consensus · miss
Revenue surprise
+37,9 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$12,00
Mean$12,00
Median$12,00
High$12,00
Spot$11,27
+6.5 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskMedium
Liquidity riskLow
Filing-based flags
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Op Margin-4,3 %Below median
Net Margin-2,8 %Below median
ROE-1,1 %Bottom quartile
Capex / Rev1,4 %Above P75
D/E0,00Above median
Cash Conv-0,12Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 11 680 sh1 grants1 insiders
- Director · Restricted Stock Units (cash settled) → Common StockAcquired 11 680grant · 2026-05-26
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- MEDIFAST INC company facts · 2026-05-28
- MEDIFAST INC 10-Q 2026-05-04 · 2026-05-28
- MEDIFAST INC 10-K 2026-02-17 · 2026-05-28
- MEDIFAST INC 10-Q 2025-11-03 · 2026-05-28
- MEDIFAST INC 10-Q 2025-08-04 · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$18M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Nicholas Mark JohnsonPresident, Chief Executive Officer
Insider activity
Net buying3 buys · 0 sellsnet $242K8 insiders · last 365d
- Director · Common StockOther 11 680 · 2026-05-26
- Director · Common StockOther 11 680 · 2026-05-26
- Director · Common StockOther 6 739 · 2026-05-26
- Director · Common StockOther 11 680 · 2026-05-26
- Director · Common StockOther 7 637 · 2026-05-26
- Director · Common StockOther 11 680 · 2026-05-26
- Director · Common StockOther 11 680 · 2026-05-26
- Director · Common StockBought 2 500 @ $12,53$31K · 2026-05-11
- Director · Common StockBought 2 500 @ $12,65$32K · 2026-05-08
- Chief Financial Officer · Common StockOther 34 344 · 2026-03-25
- Chief Financial Officer · Common StockOther 3 224 @ $9,59$31K · 2026-03-25
- Chief Financial Officer · Common StockOther 1 014 · 2026-03-25
- Director, Chairman & CEO · Common StockOther 4 827 · 2026-03-25
- Director, Chairman & CEO · Common StockOther 36 968 · 2026-03-25
- Director, Chairman & CEO · Common StockOther 20 095 @ $9,59$193K · 2026-03-25
- VP, Finance & CAO · Common StockOther 10 830 · 2026-03-25
- VP, Finance & CAO · Common StockOther 862 @ $9,59$8K · 2026-03-25
- Director, Chairman & CEO · Common StockBought 17 678 @ $10,11$179K · 2026-03-20
- Chief Financial Officer · Common StockOther 482 @ $10,05$5K · 2026-03-17
- Director, Chairman & CEO · Common StockOther 2 638 @ $10,05$27K · 2026-03-17
- VP, Finance & CAO · Common StockOther 70 @ $10,05$704 · 2026-03-17
- Director, Chairman & CEO · Common StockOther 7 075 @ $9,62$68K · 2026-03-13
- VP, Finance & CAO · Common StockOther 198 @ $9,62$2K · 2026-03-13
- Chief Financial Officer · Common StockOther 918 @ $9,62$9K · 2026-03-13
Short positioning
1.6Mshares short+5.0% vs prior
9.41days to cover
74.2%short of daily vol
1.2Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
MEDCanonical
NYSE · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskMedium
Liquidity riskLow
Source documents mention dilution or offering risk.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -38.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -72.0%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -593.8%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -33.8%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -12.8%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -5.3%Derived (calculated)
- Net margin (FY 2025-12-31): -4.9%Derived (calculated)
- Gross margin (FY 2025-12-31): 71.3%Derived (calculated)
- Return on equity (FY 2025-12-31): -9.6%Derived (calculated)
- Return on assets (FY 2025-12-31): -7.7%Derived (calculated)
- Current ratio (FY 2025-12-31): 4.69xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.25xDerived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -36.0%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -24.7%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -1.8%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -29.9%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -994.7%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -994.7%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -6.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -1,050.0%Derived (calculated)
- Current assets (annual): USD 201.68MSEC XBRL filing
- Current liabilities (annual): USD 42.96MSEC XBRL filing
- Total liabilities (annual): USD 49.05MSEC XBRL filing
- Shares outstanding (annual): 10.99MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-08-03EVENTQ2 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-05-26 00:00 UTCINSIDER10 insider transactions — 2026-05 1 derivative
2026-05-26 00:00 UTCINSIDER10 insider transactions — 2026-05 1 derivative
2026-05-26INSIDERGeary Elizabeth A. transacted 11.7k sh — Director
2026-05-26INSIDERRose Jeffrey Matthew transacted 11.7k sh — Director
2026-05-26INSIDERRose Jeffrey Matthew transacted 6.7k sh — Director
2026-05-26INSIDERKiai Parsa transacted 11.7k sh — Director
2026-05-26INSIDERKiai Parsa transacted 7.6k sh — Director
2026-05-26INSIDERThomas Andrea B transacted 11.7k sh — Director
2026-05-26INSIDERSCHLACKMAN SCOTT transacted 11.7k sh — Director
2026-05-26INSIDERXian Ming acquired 11.7k sh Restricted Stock Units (cash settled) — Director
2026-05-11INSIDERSCHLACKMAN SCOTT bought 2.5k sh — Director ~$31k
2026-05-08INSIDERSCHLACKMAN SCOTT bought 2.5k sh — Director ~$32k
2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 76.0M · Net USD -2.1M
2026-03-25 00:00 UTCINSIDER15 insider transactions — 2026-03 · net sell $164k
2026-03-25 00:00 UTCINSIDER15 insider transactions — 2026-03 · net sell $164k
2026-03-25INSIDERMaloney James P. transacted 34.3k sh — Chief Financial Officer
2026-03-25INSIDERMaloney James P. transacted 3.2k sh — Chief Financial Officer ~$31k
2026-03-25INSIDERMaloney James P. transacted 1.0k sh — Chief Financial Officer
2026-03-25INSIDERChard Daniel R transacted 4.8k sh — Director, Chairman & CEO
2026-03-25INSIDERChard Daniel R transacted 37.0k sh — Director, Chairman & CEO
2026-03-25INSIDERChard Daniel R transacted 20.1k sh — Director, Chairman & CEO ~$193k
2026-03-25INSIDERMacKenzie Jonathan Barrett transacted 10.8k sh — VP, Finance & CAO
2026-03-25INSIDERMacKenzie Jonathan Barrett transacted 862 sh — VP, Finance & CAO ~$8k
2026-03-20INSIDERChard Daniel R bought 17.7k sh — Director, Chairman & CEO ~$179k
2026-03-17INSIDERMaloney James P. transacted 482 sh — Chief Financial Officer ~$5k
2026-03-17INSIDERChard Daniel R transacted 2.6k sh — Director, Chairman & CEO ~$27k
2026-03-17INSIDERMacKenzie Jonathan Barrett transacted 70 sh — VP, Finance & CAO ~$1k
2026-03-13INSIDERChard Daniel R transacted 7.1k sh — Director, Chairman & CEO ~$68k
2026-03-13INSIDERMacKenzie Jonathan Barrett transacted 198 sh — VP, Finance & CAO ~$2k
2026-03-13INSIDERMaloney James P. transacted 918 sh — Chief Financial Officer ~$9k
Showing the 40 most recent of 56 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage